)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Innate Pharma
Innate Pharma (IPH) investor relations material
Innate Pharma Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary17 Sep, 2026
Strategic focus and portfolio overview
Focused on high-value oncology assets with in-house antibody and ADC expertise.
Portfolio includes late-stage partnered assets and a proprietary ADC pipeline.
Organization reshaped for agile execution and impact.
Key clinical assets and partnerships
Lacutamab (anti-KIR3DL2 mAb) partnered with Sobi, advancing to Phase 3 TELLOMAK-3 in CTCL, targeting accelerated approval in Sézary syndrome.
Monalizumab (anti-NKG2A mAb) co-developed with AstraZeneca, with Phase 3 PACIFIC-9 in NSCLC; Phase 2 data showed prolonged PFS with combination therapy.
IPH4502 (Nectin-4 ADC) wholly owned, with Phase 1 dose escalation completed and preliminary anti-tumor activity observed in multiple solid tumors.
Clinical data and market opportunity
Lacutamab Phase 2 showed durable responses and favorable safety in CTCL, supporting accelerated approval plans.
High unmet need in CTCL, with lacutamab positioned for significant market expansion and peak year sales potential over $500M.
IPH4502 demonstrated activity in preclinical and early clinical settings, addressing resistance and heterogeneity in solid tumors.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Innate Pharma
- $75M Sobi deal and €30M equity raise extend cash runway as late-stage trials progress.IPH
Q2 2026 - Key late-stage data and partnerships position the pipeline for major milestones and growth.IPHH.C. Wainwright 28th Annual Global Investment Conference
- Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026.IPHCompany presentation
- €30M equity raise and Sobi deal extend funding for late-stage pipeline and key data in 2024.IPHInvestor update
- Three differentiated oncology assets advance toward key clinical and commercial milestones in 2026.IPHCorporate presentation
- Rapid clinical progress and strategic partnerships drive a diverse oncology pipeline toward key milestones.IPHStifel 2025 Virtual Targeted Oncology Forum
- Lacutamab targets accelerated approval in Sézary syndrome by 2027, unlocking major CTCL market growth.IPHInvestor Update
- Strategic refocus, €15m Sanofi investment, and cost cuts support cash runway and clinical progress.IPHQ2 2025
- Strong pipeline progress, lower revenue, net loss, and €102.1m cash runway through 2025.IPHQ2 2024
Next Innate Pharma earnings date
Q3 2026 TU5 Nov, 2026
Innate Pharma
Next Innate Pharma earnings date
Q3 2026 TU5 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage